Nasdaq
$2.46▲ 1.36%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $87.0MShares out 35.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 5d agoRegular26.10.19 22:486-KKey event#●●●#●●●#●●●
NeuroSense Therapeutics Ltd.Bullish
NeuroSense Therapeutics has filed a U.S. patent application for methods of treating traumatic brain injury (TBI) using its lead drug candidate, PrimeC. This filing is part of the company's strategic effort to expand PrimeC's potential beyond its primary focus on ALS and to support future research partnerships and non-dilutive funding opportunities.…more
$2.46+1.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 21:406-KKey event
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics has secured a Nasdaq hearing date for November 10, 2026, following an appeal against a delisting determination, with trading continuing pending the panel's decision. While the company has regained compliance with the minimum bid price, it must address the minimum market value deficiency at the hearing. Upcoming milestones include a New Drug Submission to Health Canada in December 2026 and a decision on non-dilutive funding for its Phase 3 trial in Q1 2027.…more
$2.46+1.36%vs prev closeView filingShare - 10.2After-hours26.10.03 05:156-KKey event
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics has received a delisting determination from Nasdaq due to failure to meet the $35 million minimum market value of listed securities (MVLS) requirement and intends to appeal the decision before a Nasdaq Hearings Panel. Meanwhile, the company has regained compliance with the $1.00 minimum bid price requirement following a 1-for-20 reverse share split.…more
$2.46+1.36%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.19 21:28#●●●#●●●#●●●
NeuroSense Therapeutics Files U.S. Patent Application for TBI Treatment…more
NeuroSense Therapeutics has filed a U.S. patent application for a combination therapy to treat traumatic brain injuries. This move is part of the company's long-term strategy to expand the commercial potential of its lead asset beyond existing programs.…more
$2.46+1.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13Pre-market26.10.13 21:38
●●●●●●●● ●●●●● ●●●●●●
NeuroSense Therapeutics has scheduled a Nasdaq hearing for November 10 to address its market value deficiency after regaining compliance with the minimum bid price requirement. The company plans to present a plan to meet listing standards while awaiting upcoming milestones for its ALS drug, PrimeC.…more
$2.46+1.36%vs prev closeShareBenzinga - 10.2After-hours26.10.03 05:16
●●●●●●●● ●●●●● ●●●●●●
NeuroSense Therapeutics has received a notice from Nasdaq for failing to meet the minimum market value of listed securities requirement of $35 million. The company intends to appeal the decision to the Nasdaq Hearings Panel to request additional time to regain compliance.…more
$2.46+1.36%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report